Is Daptomycin plus Ceftaroline Associated with Better Clinical Outcomes than Standard of Care Monotherapy for Staphylococcus aureus Bacteremia?

Antimicrob Agents Chemother. 2019 Oct 22;63(11):e00900-19. doi: 10.1128/AAC.00900-19. Print 2019 Nov.

Authors

Andre C Kalil¹, Marisa Holubar², Stan Deresinski², Henry F Chambers³

Affiliations

¹ Division of Infectious Diseases, University of Nebraska Medical Center, Omaha, Nebraska, USA akalil@unmc.edu.
² Division of Infectious Diseases, Stanford University, Stanford, California, USA.
³ Division of Infectious Diseases, Zuckerberg San Francisco General Hospital, San Francisco, California, USA.

No abstract available

Keywords: Staphylococcus aureus; ceftaroline; clinical outcomes; daptomycin; medical outcomes; vancomycin.

Publication types

Letter
Comment

MeSH terms

Bacteremia*
Ceftaroline
Cephalosporins
Daptomycin*
Humans
Methicillin
Methicillin-Resistant Staphylococcus aureus*
Standard of Care
Staphylococcal Infections*
Staphylococcus aureus

Substances

Cephalosporins
Daptomycin
Methicillin